Ginkgo reported a fourth-quarter net loss of $1.41 per share on $33.32 million in revenue, missing consensus loss estimates of $1.36 and sales forecasts of $37.62 million. Cell engineering revenue fell 26% year-over-year to $26 million, while biosecurity sales declined to $7 million from $9 million in the prior-year quarter.

To concentrate on its autonomous labs initiative, the company will divest its biosecurity business to a consortium for a minority stake in H1 2026. Management plans to reinvest proceeds into robotics and AI capabilities, partnering with the Department of Energy and OpenAI on lab automation.

Ginkgo expects total cash burn of $125 million to $150 million in 2026 as it ramps autonomous lab operations and funds ongoing R&D in cell engineering. The company’s cash runway will depend on divestment proceeds and potential future financing.

Shares have fallen over 54% in the past 12 months and trade 18% below their 20-day SMA, reflecting bearish momentum. The RSI sits at neutral 50.00, but MACD remains negative, while analysts maintain a Hold consensus with an average price target near $170.